**S1 Table. CMV plasma virus load before and after administration of PASylated antagonist.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | CMV copies/ml | | Group proportion CMV+ | |
| Pre-  IFN-1ant | Post-  IFN-1ant | Pre-  IFN-1ant | Post-  IFN-1ant |
| +ART  Placebo | A10V012 | 6250 | 0 | 2/5 | 1.5 |
| A11E030 | 23352 | 17404 |
| ZJ06 | 0 | 0 |
| ZJ07 | 0 | 0 |
| ZJ53 | 0 | 0 |
| +ART  IFN-1ant 2x | A9P012 | 0 | 0 | 3/11 | 1/11 |
| A9V044 | 0 | 0 |
| A10E060 | 27711 | 12526 |
| A10E109 | 0 | 0 |
| A11E008 | 0 | 0 |
| A11E078 | 0 | 0 |
| BG58 | 6915 | 0 |
| BG73 | 0 | 0 |
| ZH40 | 0 | 0 |
| ZH56 | 5147 | 0 |
| ZJ24 | 0 | 0 |
| +ART  IFN-1ant 3x | 23212 | 0 | 0 | 1/5 | 0/5 |
| 25011 | 0 | 0 |
| 26311 | 0 | 0 |
| 26711 | 0 | 0 |
| 29512 | 2832 | 0 |